KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAmortizationAmortizationCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in CashChange in IntangiblesChange in IntangiblesDivestmentsDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShares IssuedShares RepurchasedShort-Term Debt issuancesShort-Term Debt repayments
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gsk (GSK) Change in Intangibles (2016 - 2026)

Gsk has reported Change in Intangibles over the past 18 years, most recently at -$299.3 million for Q1 2026.

  • For Q1 2026, Change in Intangibles rose 0.99% year-over-year to -$299.3 million; the TTM value through Mar 2026 reached -$2.2 billion, up 32.37%, while the annual FY2025 figure was -$2.2 billion, 7.17% down from the prior year.
  • Change in Intangibles for Q1 2026 was -$299.3 million at Gsk, up from -$601.2 million in the prior quarter.
  • Over five years, Change in Intangibles peaked at -$176.7 million in Q2 2024 and troughed at -$2.0 billion in Q4 2024.
  • A 5-year average of -$569.5 million and a median of -$384.1 million in 2024 define the central range for Change in Intangibles.
  • Biggest five-year swings in Change in Intangibles: skyrocketed 82.56% in 2022 and later crashed 451.18% in 2024.
  • Year by year, Change in Intangibles stood at -$1.3 billion in 2022, then surged by 71.81% to -$368.6 million in 2023, then tumbled by 451.18% to -$2.0 billion in 2024, then skyrocketed by 70.41% to -$601.2 million in 2025, then surged by 50.22% to -$299.3 million in 2026.
  • Business Quant data shows Change in Intangibles for GSK at -$299.3 million in Q1 2026, -$601.2 million in Q4 2025, and -$766.4 million in Q3 2025.